SE0101982D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0101982D0
SE0101982D0 SE0101982A SE0101982A SE0101982D0 SE 0101982 D0 SE0101982 D0 SE 0101982D0 SE 0101982 A SE0101982 A SE 0101982A SE 0101982 A SE0101982 A SE 0101982A SE 0101982 D0 SE0101982 D0 SE 0101982D0
Authority
SE
Sweden
Prior art keywords
ethoxy
pharmaceutical combination
phenyl
propanoic acid
methanesulfonyloxyphenyl
Prior art date
Application number
SE0101982A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Oehman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101982A priority Critical patent/SE0101982D0/xx
Publication of SE0101982D0 publication Critical patent/SE0101982D0/xx
Priority to HU0401613A priority patent/HUP0401613A3/hu
Priority to EP02736370A priority patent/EP1399166A1/en
Priority to PCT/SE2002/001036 priority patent/WO2002100413A1/en
Priority to SK1472-2003A priority patent/SK14722003A3/sk
Priority to US10/479,205 priority patent/US20040157927A1/en
Priority to PL02367890A priority patent/PL367890A1/pl
Priority to EEP200300583A priority patent/EE200300583A/xx
Priority to IL15903502A priority patent/IL159035A0/xx
Priority to KR10-2003-7015644A priority patent/KR20040007624A/ko
Priority to CZ20033235A priority patent/CZ20033235A3/cs
Priority to CNB028149882A priority patent/CN1250226C/zh
Priority to MXPA03011010A priority patent/MXPA03011010A/es
Priority to CA002448763A priority patent/CA2448763A1/en
Priority to RU2003136157/15A priority patent/RU2003136157A/ru
Priority to JP2003503234A priority patent/JP2004532891A/ja
Priority to BR0210127-0A priority patent/BR0210127A/pt
Priority to NO20035235A priority patent/NO20035235D0/no
Priority to ZA200309263A priority patent/ZA200309263B/en
Priority to IS7057A priority patent/IS7057A/is
Priority to CO03112113A priority patent/CO5540382A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0101982A 2001-06-01 2001-06-01 Pharmaceutical combination SE0101982D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
BR0210127-0A BR0210127A (pt) 2001-06-01 2002-05-30 Composição farmacêutica, métodos de tratamento ou prevenção de diabetes e de tratamento da sìndrome de resistência à insulina, kit de partes, preparação combinada, e, método para a produção de um kit de partes
IL15903502A IL159035A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3- [4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3- {4- [2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}- (s) -2-ethoxy propanoic acid and a sulfonylurea
CZ20033235A CZ20033235A3 (cs) 2001-06-01 2002-05-30 Farmaceutická kombinace
PCT/SE2002/001036 WO2002100413A1 (en) 2001-06-01 2002-05-30 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA
SK1472-2003A SK14722003A3 (sk) 2001-06-01 2002-05-30 Farmaceutická kombinácia obsahujúca buď kyselinu (S)-2-etoxy-3- [4-(2-{4-metánsulfonyloxyfenyl}-etoxy)fenyl]propánovú, alebo kyselinu 3-{4-[2-(4-terc-butoxykarbonylaminofenyl)etoxy]fenyl}- (S)-2-etoxypropánovú a sulfonylmočovinu
US10/479,205 US20040157927A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{-4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and a sulonylurea
PL02367890A PL367890A1 (pl) 2001-06-01 2002-05-30 Kombinacja farmaceutyczna obejmująca albo kwas (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowy albo kwas 3-{4-[2(4-tert-butoksykarbonyloaminofenylo) etoksy] fenylo}-(S)-2-etoksypropanowy oraz sulfonylomocznik
EEP200300583A EE200300583A (et) 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja sulfonüüluureat
HU0401613A HUP0401613A3 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2)-{4-methane sulfonyl oxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and a sulonylurea
KR10-2003-7015644A KR20040007624A (ko) 2001-06-01 2002-05-30 (Ｓ)-2-에톡시-3-[4-(2-｛4-메탄설포닐옥시페닐｝에톡시)페닐] 프로판산 또는3-｛4-[2-(4-ｔ-부톡시카르보닐아미노페닐)에톡시]페닐｝-(Ｓ)-2-에톡시 프로판산 및 설포닐우레아를 포함하는 약학조합물
EP02736370A EP1399166A1 (en) 2001-06-01 2002-05-30 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- 4-(2- 4-METHANE SULFONYL OXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID OR 3- 4- 2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA
CNB028149882A CN1250226C (zh) 2001-06-01 2002-05-30 一种包含(s)－2－乙氧基－3－[4－(2－{4－甲磺酰基氧基苯基}乙氧基)苯基]丙酸或3－{4－[2－(4－叔丁氧基羰基氨基苯基)乙氧基]苯基}－(s)－2－乙氧基丙酸和磺酰脲的联合药物
MXPA03011010A MXPA03011010A (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoxi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil] propanoico o acido 3-{4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico y una sulfonilurea.
CA002448763A CA2448763A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
RU2003136157/15A RU2003136157A (ru) 2001-06-01 2002-05-30 Фармацевтическая комбинация, содержащая либо (s)-2-этокси-3-{4-метансульфонилоксифенил}-пропионовую кислоту, либо 3-{4-[2-(4-трет-бутоксикарбониламинофенил) этокси]фенил}-(s)-этоксипропионовую кислоту и сульфонилмочевину
JP2003503234A JP2004532891A (ja) 2001-06-01 2002-05-30 （Ｓ）−２−エトキシ−３−［４−（２−｛４−メタンスルホニルオキシフェニル｝エトキシ）フェニル］プロパン酸かまたは３−｛４−［２−（４−ｔｅｒｔ−ブトキシカルボニルアミノフェニル）エトキシ］フェニル｝−（Ｓ）−２−エトキシプロパン酸およびスルホニル尿素を含む医薬組合せ
NO20035235A NO20035235D0 (no) 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3- (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)
ZA200309263A ZA200309263B (en) 2001-06-01 2003-11-27 A pharmaceutical combination comprising either (S)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl) propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl) ethoxyl phenyl} -(S)-2-ethoxy propanoic acid and a sulfonylurea.
IS7057A IS7057A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni
CO03112113A CO5540382A2 (es) 2001-06-01 2003-12-23 UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI) FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERTBUTOXI CARBONIL AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO Y UNA SULFONILUREA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0101982D0 true SE0101982D0 (sv) 2001-06-01

Family

ID=20284364

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101982A SE0101982D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Country Status (21)

Country Link
US (1) US20040157927A1 (pl)
EP (1) EP1399166A1 (pl)
JP (1) JP2004532891A (pl)
KR (1) KR20040007624A (pl)
CN (1) CN1250226C (pl)
BR (1) BR0210127A (pl)
CA (1) CA2448763A1 (pl)
CO (1) CO5540382A2 (pl)
CZ (1) CZ20033235A3 (pl)
EE (1) EE200300583A (pl)
HU (1) HUP0401613A3 (pl)
IL (1) IL159035A0 (pl)
IS (1) IS7057A (pl)
MX (1) MXPA03011010A (pl)
NO (1) NO20035235D0 (pl)
PL (1) PL367890A1 (pl)
RU (1) RU2003136157A (pl)
SE (1) SE0101982D0 (pl)
SK (1) SK14722003A3 (pl)
WO (1) WO2002100413A1 (pl)
ZA (1) ZA200309263B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I

Also Published As

Publication number Publication date
IL159035A0 (en) 2004-05-12
CA2448763A1 (en) 2002-12-19
JP2004532891A (ja) 2004-10-28
US20040157927A1 (en) 2004-08-12
CZ20033235A3 (cs) 2004-12-15
CO5540382A2 (es) 2005-07-29
CN1537008A (zh) 2004-10-13
EE200300583A (et) 2004-02-16
HUP0401613A2 (hu) 2004-11-29
SK14722003A3 (sk) 2004-08-03
MXPA03011010A (es) 2004-02-27
PL367890A1 (pl) 2005-03-07
CN1250226C (zh) 2006-04-12
ZA200309263B (en) 2005-03-11
WO2002100413A1 (en) 2002-12-19
KR20040007624A (ko) 2004-01-24
EP1399166A1 (en) 2004-03-24
RU2003136157A (ru) 2005-05-20
NO20035235D0 (no) 2003-11-25
IS7057A (is) 2003-11-28
BR0210127A (pt) 2004-06-08
HUP0401613A3 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
NO20022591D0 (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
NO20013674L (no) Acetyleniske <alfa>-aminosyre-baserte sulfonamid- hydroksamsyre TACE-inhibitorer
NO20033941D0 (no) Sammensetning som forbedrer aldersrelaterte fysiologiske mangler som forlenger levetiden
BR0317715A (pt) Composições e processos de uso de collajolie
HRP20010580B1 (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
IT1318056B1 (it) Proiettore luminoso particolarmente per la proiezione di luce adimensioni variabili e ad infiniti colori.
DE60231163D1 (de) Negativ aufladbarer Toner
ATE341544T1 (de) Sulfonamide
DK1237855T3 (da) Krystallinsk form af (S)-2-ethoxy-3-[4-(2-(4-methansulfonyloxyphenyl)ethoxy)phenyl]propansyre
EE200400023A (et) Uued sulfoonhappe derivaadid
EP1293850A4 (en) INFORMATION PROCESSOR
SE0101981D0 (sv) Pharmaceutical combination
IS7058A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf
MXPA03011010A (es) Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoxi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil] propanoico o acido 3-{4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico y una sulfonilurea.
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
ES2571834T3 (es) Alquilsulfonamida quinolinas
BRPI0418226A (pt) preparação de cloridrato r-5-(2-(2-(2-etoxifenoxietilamino) propil-2-metoxibenzenossulfonamida de alta pureza quìmica
CO4650180A1 (es) Derivados de alquil-5-metilsulfonil-benzoilguanidinas
ATE482952T1 (de) Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid
HK1062527A (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
ATE395949T1 (de) Kosmetische zusammensetzungen enthaltend ein amphoteres tensid und ein ceramid sowie ihre verwedung
AR030731A1 (es) Nuevas formas de sales solidas de n-(2-(4-[2-(1-metiletoxi)fenil]-1-piperazinil]etil]-2-oxo-1-piperidinacetamida
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt